Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
These findings follow positive Phase 3 results presented earlier this year
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
IND application for EB-003 expected in early 2026
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations
Subscribe To Our Newsletter & Stay Updated